Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 286

1.

The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis.

Arends S, Lebbink HR, Spoorenberg A, Bungener LB, Roozendaal C, van der Veer E, Houtman PM, Griep EN, Limburg PC, Kallenberg CG, Wolbink GJ, Brouwer E.

Clin Exp Rheumatol. 2010 Sep-Oct;28(5):661-8. Epub 2010 Oct 22.

PMID:
20822711
2.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

3.

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.

Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A.

Arthritis Res Ther. 2011 Jun 20;13(3):R94. doi: 10.1186/ar3369.

4.

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.

Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H.

Arthritis Res Ther. 2010;12(3):R117. doi: 10.1186/ar3054. Epub 2010 Jun 16.

5.

Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis.

Benucci M, Saviola G, Baiardi P, Cammelli E, Manfredi M.

Clin Rheumatol. 2008 Jan;27(1):91-5. Epub 2007 Oct 10.

PMID:
17929076
6.

Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.

Gonnet-Gracia C, Barnetche T, Richez C, Blanco P, Dehais J, Schaeverbeke T.

Clin Exp Rheumatol. 2008 May-Jun;26(3):401-7.

PMID:
18578960
7.

Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study.

Spadaro A, Lubrano E, Marchesoni A, D'Angelo S, Ramonda R, Addimanda O, Perrotta FM, Olivieri I, Punzi L, Salvarani C.

Rheumatology (Oxford). 2013 Oct;52(10):1914-9. doi: 10.1093/rheumatology/ket249. Epub 2013 Jul 22.

8.

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.

de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, van Denderen JC, Dijkmans BA, Wolbink GJ.

Ann Rheum Dis. 2009 Apr;68(4):531-5. doi: 10.1136/ard.2008.089979. Epub 2008 Mar 28.

PMID:
18375542
9.

Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.

de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, Hazenberg BP, Wolbink GJ.

Arthritis Rheum. 2009 Nov 15;61(11):1484-90. doi: 10.1002/art.24838.

10.

The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.

Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB.

Semin Arthritis Rheum. 2004 Feb;33(4):283-8.

PMID:
14978666
11.
12.
13.

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.

Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, Dijkmans BA, Aarden L, Wolbink GJ.

Ann Rheum Dis. 2011 Feb;70(2):284-8. doi: 10.1136/ard.2010.135111. Epub 2010 Nov 10.

PMID:
21068090
14.

Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis.

Zisapel M, Zisman D, Madar-Balakirski N, Arad U, Padova H, Matz H, Maman-Sarvagyl H, Kaufman I, Paran D, Feld J, Litinsky I, Wigler I, Caspi D, Elkayam O.

J Rheumatol. 2015 Jan;42(1):73-8. doi: 10.3899/jrheum.140685. Epub 2014 Nov 15.

PMID:
25399390
15.
16.

Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy.

Kwon SR, Lim MJ, Suh CH, Park SG, Hong YS, Yoon BY, Kim HA, Choi HJ, Park W.

Rheumatol Int. 2012 Aug;32(8):2523-7. doi: 10.1007/s00296-011-1981-0. Epub 2011 Jul 16.

PMID:
21833531
17.

Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-alpha treatment response in rheumatoid arthritis.

Dejaco C, Duftner C, Klotz W, Schirmer M, Herold M.

Rheumatol Int. 2010 Feb;30(4):451-4. doi: 10.1007/s00296-009-0978-4. Epub 2009 Jun 9.

PMID:
19506882
18.

Monoclonal anti-TNF antibodies can elevate hemoglobin level in patients with ankylosing spondylitis.

Bes C, Yazici A, Soy M.

Rheumatol Int. 2013 Jun;33(6):1415-8. doi: 10.1007/s00296-012-2539-5. Epub 2012 Nov 13.

PMID:
23143665
19.

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.

Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ.

Ann Rheum Dis. 2010 May;69(5):817-21. doi: 10.1136/ard.2009.112847. Epub 2009 Jul 5.

PMID:
19581278
20.

Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis.

Arends S, van der Veer E, Groen H, Houtman PM, Jansen TL, Leijsma MK, Bijzet J, Limburg PC, Kallenberg CG, Spoorenberg A, Brouwer E.

J Rheumatol. 2011 Aug;38(8):1644-50. doi: 10.3899/jrheum.101128. Epub 2011 Jun 1.

PMID:
21632677
Items per page

Supplemental Content

Write to the Help Desk